Mr. Ellis serves as the Chairman of the Board for January Therapeutics as well as the Chief Executive Officer. Mr. Ellis is an entrepreneur, business leader, investor, biochemist and molecular biologist who has worked in the biotechnology industry for over 20 years.
He has successfully grown multiple businesses including Thomson Instrument Company and is listed as inventor on more than 35+ patents. In his career Sam has successfully closed more than 100 deals in biotechnology-focused partnerships with large pharma, small pharma, academic, and government entities. He has collaborated to publish together with Genentech, Pfizer, Takeda, and other companies in ground breaking scientific areas. Sam is a regular speaker at PEP Talk & PEGS, speaking publicly at multiple conferences, and regularly gives technical seminars at companies around the world.
In addition to his executive role at Thomson, Mr. Ellis is actively involved in life science investment firms, including Life Science Angels and Tech Coast Angels. Mr. Ellis educational background is in biochemistry and molecular biology, in which he received his B.S. from the University of California, San Diego. Mr. Ellis is also an inventor holding over 40 patents.
Dr. Maneval joined the company as Chief Scientific Officer after serving as Vice President for Research and Nonclinical Development at Halozyme Therapeutics, where he played a key role in the development of FDA approved products (e.g., HYQVIA®, HYCELA®, HYLECTA®) with the company’s drug delivery technology.
Dr. Maneval is a scientific leader with 30+ years of experience in the preclinical and early clinical development of novel biotherapeutics for cancer and other unmet medical needs. He conducted IND-enabling studies for HERCEPTIN®, and advanced the early-stage development of several adenovirus-based therapeutics (e.g., ADSTILLADRIN®) at Schering-Plough’s center for gene therapy, Dr. Maneval has co-authored more than 50 scientific publications and is a co-inventor on 14 patents.
Dr. Maneval holds a B.S. in Biomedical Engineering from Boston University, M.S. and Ph.D. degrees in Biomedical Engineering from the University of Southern California, and he completed postdoctoral training at St. Jude Children’s Research Hospital.
Dr. Walling is the Chief Medical Officer for January Therapeutics. Dr. Walling is a seasoned MD, PhD pharmaceutical executive with extensive experience in the global clinical development of anticancer drugs and drugs for rare genetic diseases. She is also an expert in the technical assessment of licensing opportunities within these fields.
In the field of drug development, Dr. Walling has over 25 years of experience in oncology as well as several years experience in rare genetic disease development.
Dr. Walling has held senior positions at Eli Lilly, Tularik, Axys Pharmaceuticals, BioMarin, in addition to serving as a resident for the UK’s National Health Services.
Dr. Walling received her medical degree from University of Bristol and her PhD from the University of Southampton.
Dr. Kearney is a former Senior Director of Medicinal Chemistry at Exelixis, where he led teams whose kinase-focused efforts resulted in multiple clinical candidates for oncology and inflammation applications.
Additionally, while there, he led both technology development, production, and corporate partnership initiatives to build the company’s screening library. Subsequently, Dr. Kearney founded of HD Sciences to develop nanoparticle-based reagents for use in medicinal chemistry. Immediately prior to joining January Therapeutics, he was a Principal Investigator in Chemistry at Deciphera Pharmaceuticals, where led a team to identify novel kinase inhibitors with that company’s core technology platform.
Dr. Kearney received his B.S. from Carnegie Mellon University and a Ph.D. in Chemistry from the California Institute of Technology. He is listed as an inventor on 20 patent applications and as an author on 17 peer-reviewed articles.
Dr. Curt Monnig joined the company as Head of CMC (Chemistry, Manufacturing, and Control). Dr. Monnig joined the team after supporting the successful CMC actives at Nalproprion.
Dr. Monnig has authored or reviewed sections in 28+ investigational drug requests (IND, IMPD, etc) covering products ranging from Phase I through Phase III. He has also authored or submitted supporting documents for 10+ marketing authorization requests (NDA, BLA, MAA, etc.). Dr. Monnig has led face-to-face interactions with the US FDA, US CDC, Irish HPRA and Korean MFDS.
Dr. Monnig earned his undergraduate and graduate degrees from the University of Missouri and his Ph.D. in Chemistry from Indiana University. His previous experience includes UC Riverside, Amylin Pharmaceuticals, Cardinal Health, Allergan, and Orexigen Therapeutics.
Don Rindell has more than 30 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development, and device/technology strategy for several US and European pharmaceutical and medical device companies.
Mr. Rindell is currently Managing Director of Camino International, LLC, a consulting practice for Business and Product Development. He recently managed the partnered pharmaco-diagnostic programs for Bristol Myers Squibb’s Translational Medicine initiatives for oncology and fibrosis. Previously he served as Senior Director of Corporate Development at Amylin Pharmaceuticals, which was purchased by Bristol Myers Squibb. At Amylin, he led a number of key global transactions with companies including Shionogi Pharmaceuticals, Biocon, Takeda Pharmaceuticals and selected device delivery companies. He also provided management leadership to the Amylin Drug Delivery Team. He has previously held senior executive positions at CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, Hybritech, and Syntex.
Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.
Norm Herman has joined January as an advisor for CMC/Formulation/Partnership Relations. Norm has over 25+ years in pharmaceutical development and manufacturing, specializing in oral dosage product development and drug delivery manufacturing.
Norm’s previous work at Halozyme contributed to very successful partnering deals with their technology to numerous companies. His other successes at Purdue Pharma, and Lederle have helped shaped his understanding of drug delivery.
Copyright © 2021 January Therapeutics - All Rights Reserved.